Named on one round in the feed.
Since 2026-01-08
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Diagonal Therapeutics They develop innovative clustering antibodies for the treatment of genetic diseases. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $125M | 2026-01-08 | [ PART ] |